
ProMIS Neurosciences Investor Relations Material
Latest events

Q1 2025
12 May, 2025

Q4 2024
31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ProMIS Neurosciences Inc
Access all reports
ProMIS Neurosciences Inc is a Canada-based biotechnology company focused on the discovery and development of antibody therapeutics for neurodegenerative diseases. The company uses a proprietary computational platform to design monoclonal antibodies that selectively target toxic misfolded proteins implicated in conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. ProMIS conducts preclinical and early-stage clinical development in collaboration with academic and industry partners. The company is headquartered in Toronto, Ontario, and its shares are listed on the TSX.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
PMN
Country
🇺🇸 United States